Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC lifted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 61,129 shares of the company’s stock after acquiring an additional 831 shares during the period. Capstone Investment Advisors LLC’s holdings in Intellia Therapeutics were worth $1,256,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Blue Trust Inc. boosted its holdings in Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the last quarter. Eastern Bank acquired a new position in Intellia Therapeutics in the third quarter valued at about $41,000. First Horizon Advisors Inc. boosted its position in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares during the period. Finally, Values First Advisors Inc. purchased a new position in shares of Intellia Therapeutics during the third quarter worth $54,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Trading Up 3.3 %

NTLA stock opened at $15.21 on Friday. The company has a fifty day moving average price of $17.38 and a 200 day moving average price of $21.47. Intellia Therapeutics, Inc. has a 12 month low of $12.82 and a 12 month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The business’s quarterly revenue was down 24.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.38) EPS. Analysts forecast that Intellia Therapeutics, Inc. will post -5.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on NTLA shares. Wells Fargo & Company lowered their target price on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, November 18th. Chardan Capital increased their target price on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, November 18th. Wedbush restated a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. William Blair reiterated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Finally, The Goldman Sachs Group cut their price target on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $54.94.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is currently owned by insiders.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.